Loading…
Factors associated with prescribing restriction on oncology formulary drugs in Malaysia
Background Drugs listed on formularies are often subjected to a variety of utilization restriction measures. However, the degree of restriction is influenced by multiple factors, including the characteristics and attributes of the listed drugs. Objective To identify the factors that are associated w...
Saved in:
| Published in: | International journal of clinical pharmacy 2016-10, Vol.38 (5), p.1075-1079 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c357t-fe4371858ab386fb15776412226e889d705dd8cc0f070679b96eab87d402c8b63 |
| container_end_page | 1079 |
| container_issue | 5 |
| container_start_page | 1075 |
| container_title | International journal of clinical pharmacy |
| container_volume | 38 |
| creator | Fatokun, Omotayo Olawepo, Michael N. |
| description | Background
Drugs listed on formularies are often subjected to a variety of utilization restriction measures. However, the degree of restriction is influenced by multiple factors, including the characteristics and attributes of the listed drugs.
Objective
To identify the factors that are associated with the levels of prescribing restriction on oncology formulary drugs in Malaysia.
Setting
Oncology formulary in Malaysia.
Method
The Malaysia Drug Code assigned to each of the drug products on the Malaysia Ministry of Health (MOH) drug formulary was used to identify oncology drugs belonging to WHO ATC class L (antineoplastic and immunomodulating agents).
Main outcome measures
Categories of prescribing restrictions, therapeutic class, drug type, administration mode, number of sources and the post-approval use period.
Results
Oncology drugs having a shorter post-approval use period (
p
|
| doi_str_mv | 10.1007/s11096-016-0372-8 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827913970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1823034537</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-fe4371858ab386fb15776412226e889d705dd8cc0f070679b96eab87d402c8b63</originalsourceid><addsrcrecordid>eNqNkcFKAzEQhoMotmgfwIsEvHhZzSS7SfYoxaqgeFE8hmw2WyPbTU12kb69qa1FBMGQMAP55s9kfoROgFwAIeIyApCSZwTSYYJmcg-NKQWSCQGwv8sJG6FJjG8krZxTKPJDNKKikJwJGKOXmTa9DxHrGL1xurc1_nD9K14GG01wlevmOKV9cKZ3vsNf2_jWz1e48WExtDqscB2GecSuww-61avo9DE6aHQb7WQbj9Dz7PppepvdP97cTa_uM8MK0WeNzVMbspC6YpI3FRRC8BwopdxKWdaCFHUtjSENEYSLsiq51ZUUdU6okRVnR-h8o7sM_n1IfaqFi8a2re6sH6ICSUUJrExz-AfKCMsLJhJ69gt980Po0kfWFCV5zqFIFGwoE3yMwTZqGdwijUMBUWuP1MYjlTxSa4-UTDWnW-WhWth6V_HtSALoBojpqpvb8OPpP1U_AXW5ms8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1822044615</pqid></control><display><type>article</type><title>Factors associated with prescribing restriction on oncology formulary drugs in Malaysia</title><source>Springer Nature</source><creator>Fatokun, Omotayo ; Olawepo, Michael N.</creator><creatorcontrib>Fatokun, Omotayo ; Olawepo, Michael N.</creatorcontrib><description>Background
Drugs listed on formularies are often subjected to a variety of utilization restriction measures. However, the degree of restriction is influenced by multiple factors, including the characteristics and attributes of the listed drugs.
Objective
To identify the factors that are associated with the levels of prescribing restriction on oncology formulary drugs in Malaysia.
Setting
Oncology formulary in Malaysia.
Method
The Malaysia Drug Code assigned to each of the drug products on the Malaysia Ministry of Health (MOH) drug formulary was used to identify oncology drugs belonging to WHO ATC class L (antineoplastic and immunomodulating agents).
Main outcome measures
Categories of prescribing restrictions, therapeutic class, drug type, administration mode, number of sources and the post-approval use period.
Results
Oncology drugs having a shorter post-approval use period (
p
< 0.001), biologic oncology drugs (
p
= 0.01) and oncology drugs belonging to immunosuppressant therapeutic class (
p
= 0.03) were all significantly associated with a greater likelihood of being subjected to a higher level of prescribing restriction.
Conclusion
This study suggests that safety concerns, costs and potentials for inappropriate use were the important considerations influencing a higher level of prescribing restriction placement on oncology drugs in the Malaysia MOH drug formulary.</description><identifier>ISSN: 2210-7703</identifier><identifier>EISSN: 2210-7711</identifier><identifier>DOI: 10.1007/s11096-016-0372-8</identifier><identifier>PMID: 27586371</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Cancer therapies ; Decision making ; Drug Prescriptions - standards ; Drug therapy ; Female ; Health Personnel - standards ; Humans ; Internal Medicine ; Malaysia - epidemiology ; Male ; Medicine ; Medicine & Public Health ; Neoplasms - drug therapy ; Neoplasms - epidemiology ; Pharmacopoeias as Topic - standards ; Pharmacy ; Prescription drugs ; Short Research Report</subject><ispartof>International journal of clinical pharmacy, 2016-10, Vol.38 (5), p.1075-1079</ispartof><rights>Springer International Publishing 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-fe4371858ab386fb15776412226e889d705dd8cc0f070679b96eab87d402c8b63</cites><orcidid>0000-0002-1231-570X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27586371$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fatokun, Omotayo</creatorcontrib><creatorcontrib>Olawepo, Michael N.</creatorcontrib><title>Factors associated with prescribing restriction on oncology formulary drugs in Malaysia</title><title>International journal of clinical pharmacy</title><addtitle>Int J Clin Pharm</addtitle><addtitle>Int J Clin Pharm</addtitle><description>Background
Drugs listed on formularies are often subjected to a variety of utilization restriction measures. However, the degree of restriction is influenced by multiple factors, including the characteristics and attributes of the listed drugs.
Objective
To identify the factors that are associated with the levels of prescribing restriction on oncology formulary drugs in Malaysia.
Setting
Oncology formulary in Malaysia.
Method
The Malaysia Drug Code assigned to each of the drug products on the Malaysia Ministry of Health (MOH) drug formulary was used to identify oncology drugs belonging to WHO ATC class L (antineoplastic and immunomodulating agents).
Main outcome measures
Categories of prescribing restrictions, therapeutic class, drug type, administration mode, number of sources and the post-approval use period.
Results
Oncology drugs having a shorter post-approval use period (
p
< 0.001), biologic oncology drugs (
p
= 0.01) and oncology drugs belonging to immunosuppressant therapeutic class (
p
= 0.03) were all significantly associated with a greater likelihood of being subjected to a higher level of prescribing restriction.
Conclusion
This study suggests that safety concerns, costs and potentials for inappropriate use were the important considerations influencing a higher level of prescribing restriction placement on oncology drugs in the Malaysia MOH drug formulary.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Cancer therapies</subject><subject>Decision making</subject><subject>Drug Prescriptions - standards</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health Personnel - standards</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Malaysia - epidemiology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - epidemiology</subject><subject>Pharmacopoeias as Topic - standards</subject><subject>Pharmacy</subject><subject>Prescription drugs</subject><subject>Short Research Report</subject><issn>2210-7703</issn><issn>2210-7711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkcFKAzEQhoMotmgfwIsEvHhZzSS7SfYoxaqgeFE8hmw2WyPbTU12kb69qa1FBMGQMAP55s9kfoROgFwAIeIyApCSZwTSYYJmcg-NKQWSCQGwv8sJG6FJjG8krZxTKPJDNKKikJwJGKOXmTa9DxHrGL1xurc1_nD9K14GG01wlevmOKV9cKZ3vsNf2_jWz1e48WExtDqscB2GecSuww-61avo9DE6aHQb7WQbj9Dz7PppepvdP97cTa_uM8MK0WeNzVMbspC6YpI3FRRC8BwopdxKWdaCFHUtjSENEYSLsiq51ZUUdU6okRVnR-h8o7sM_n1IfaqFi8a2re6sH6ICSUUJrExz-AfKCMsLJhJ69gt980Po0kfWFCV5zqFIFGwoE3yMwTZqGdwijUMBUWuP1MYjlTxSa4-UTDWnW-WhWth6V_HtSALoBojpqpvb8OPpP1U_AXW5ms8</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Fatokun, Omotayo</creator><creator>Olawepo, Michael N.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-1231-570X</orcidid></search><sort><creationdate>20161001</creationdate><title>Factors associated with prescribing restriction on oncology formulary drugs in Malaysia</title><author>Fatokun, Omotayo ; Olawepo, Michael N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-fe4371858ab386fb15776412226e889d705dd8cc0f070679b96eab87d402c8b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Cancer therapies</topic><topic>Decision making</topic><topic>Drug Prescriptions - standards</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health Personnel - standards</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Malaysia - epidemiology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - epidemiology</topic><topic>Pharmacopoeias as Topic - standards</topic><topic>Pharmacy</topic><topic>Prescription drugs</topic><topic>Short Research Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fatokun, Omotayo</creatorcontrib><creatorcontrib>Olawepo, Michael N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of clinical pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fatokun, Omotayo</au><au>Olawepo, Michael N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors associated with prescribing restriction on oncology formulary drugs in Malaysia</atitle><jtitle>International journal of clinical pharmacy</jtitle><stitle>Int J Clin Pharm</stitle><addtitle>Int J Clin Pharm</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>38</volume><issue>5</issue><spage>1075</spage><epage>1079</epage><pages>1075-1079</pages><issn>2210-7703</issn><eissn>2210-7711</eissn><abstract>Background
Drugs listed on formularies are often subjected to a variety of utilization restriction measures. However, the degree of restriction is influenced by multiple factors, including the characteristics and attributes of the listed drugs.
Objective
To identify the factors that are associated with the levels of prescribing restriction on oncology formulary drugs in Malaysia.
Setting
Oncology formulary in Malaysia.
Method
The Malaysia Drug Code assigned to each of the drug products on the Malaysia Ministry of Health (MOH) drug formulary was used to identify oncology drugs belonging to WHO ATC class L (antineoplastic and immunomodulating agents).
Main outcome measures
Categories of prescribing restrictions, therapeutic class, drug type, administration mode, number of sources and the post-approval use period.
Results
Oncology drugs having a shorter post-approval use period (
p
< 0.001), biologic oncology drugs (
p
= 0.01) and oncology drugs belonging to immunosuppressant therapeutic class (
p
= 0.03) were all significantly associated with a greater likelihood of being subjected to a higher level of prescribing restriction.
Conclusion
This study suggests that safety concerns, costs and potentials for inappropriate use were the important considerations influencing a higher level of prescribing restriction placement on oncology drugs in the Malaysia MOH drug formulary.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>27586371</pmid><doi>10.1007/s11096-016-0372-8</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-1231-570X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2210-7703 |
| ispartof | International journal of clinical pharmacy, 2016-10, Vol.38 (5), p.1075-1079 |
| issn | 2210-7703 2210-7711 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1827913970 |
| source | Springer Nature |
| subjects | Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Cancer therapies Decision making Drug Prescriptions - standards Drug therapy Female Health Personnel - standards Humans Internal Medicine Malaysia - epidemiology Male Medicine Medicine & Public Health Neoplasms - drug therapy Neoplasms - epidemiology Pharmacopoeias as Topic - standards Pharmacy Prescription drugs Short Research Report |
| title | Factors associated with prescribing restriction on oncology formulary drugs in Malaysia |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T20%3A22%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20associated%20with%20prescribing%20restriction%20on%20oncology%20formulary%20drugs%20in%20Malaysia&rft.jtitle=International%20journal%20of%20clinical%20pharmacy&rft.au=Fatokun,%20Omotayo&rft.date=2016-10-01&rft.volume=38&rft.issue=5&rft.spage=1075&rft.epage=1079&rft.pages=1075-1079&rft.issn=2210-7703&rft.eissn=2210-7711&rft_id=info:doi/10.1007/s11096-016-0372-8&rft_dat=%3Cproquest_cross%3E1823034537%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c357t-fe4371858ab386fb15776412226e889d705dd8cc0f070679b96eab87d402c8b63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1822044615&rft_id=info:pmid/27586371&rfr_iscdi=true |